ArticleTranslational vision science & technology2025
Early Fluctuations of Exudative Lesions as Predictors of Two-Year Clinical Outcomes in Neovascular Age-Related Macular Degeneration.
Article in Translational vision science & technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Geometric and concavity characteristics as diagnostic markers for differentiating nAMD-related MNV from pachychoroid neovascularisation.Eye (London, England) · 2026Article
- Real-world comparative effectiveness of faricimab versus aflibercept 2 mg in treatment-naïve exudative neovascular AMD patients treated with a treat-and-extend regimen.Eye (London, England) · 2026Article
- Indocyanine green angiography and machine learning analysis determine topographic distribution of peripheral hard drusen in a Chinese cohort.Communications medicine · 2026Article
- Longitudinal Tracking of Photoreceptor Integrity in Neovascular AMD: Early Restoration Predicts 24-Month Structural and Visual Outcomes.Investigative ophthalmology & visual science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To investigate how early fluctuations of exudative lesions correlate with 2-year outcomes in neovascular age-related macular degeneration (nAMD). Methods: This prospective study included 92 treatment-naïve nAMD eyes treated with anti-vascular endothelial growth factor (anti-VEGF) therapy using a 3+PRN regimen over 2 years. Volumes of seven exudative lesion types were measured: subretinal fluid (SRF); intraretinal fluid (IRF); vascular and avascular subretinal hyperreflective material (vSHRM and avSHRM, respectively); and serous, fibrovascular, and hemorrhagic pigment epithelial detachment (sPED, fvPED, and hPED, respectively). Four fluctuation parameters were calculated during the 3-month loading phase. Relationships between these early fluctuations and clinical outcomes, including best-corrected visual acuity (BCVA) and injection frequency, were analyzed. Results: A total of 92 eyes (92 patients) were included, with a mean age of 65.65 ± 7.20 years. After adjusting for baseline characteristics, fluctuations in both vSHRM and avSHRM were identified as independent predictors of 2-year BCVA prognosis, with greater fluctuations associated with poorer visual outcomes (vSHRM Stdβ range, 0.671-0.797; avSHRM Stdβ range, 0.722-0.856; all P ≤ 0.001). However, only IRF fluctuation metrics were found to be independently associated with injection frequency over 2 years (Stdβ range, 0.327-0.532; all P < 0.05), with greater fluctuations correlating with more frequent injections. Conclusions: SHRM fluctuations during the loading phase predict 2-year visual outcomes, and IRF variations correlate with injection frequency in nAMD. Translational Relevance: Early fluctuation patterns of exudative lesions can serve as predictive biomarkers to guide personalized anti-VEGF treatment strategies and optimize long-term visual outcomes in nAMD patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.